EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Health-related quality of life in patients with aggressive non-Hodgkin lymphoma: results from the PETAL trial

Ulrich Dührsen, Gabriele Prange-Krex, Regina Moeller, Harald Held, Gerhard Heil, Andreas Schwarzer, Stefan Mahlmann, Ariane Dienst, Matthias Sandmann, Georg Maschmeyer, Jochen Schütte, Dennis Hahn und 5 weitere

Annals of Hematology · 2025

DOI: 10.1007/s00277-025-06402-1 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Annals of Hematology, 2025. Verfasst von Ulrich Dührsen und 16 weiteren Autor:innen. Beteiligte Einrichtung: Klinik für Hämatologie und Stammzelltransplantation, Universitätsklinikum Essen, Essen, Germany. ulrich.duehrsen@uk-essen.de. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Lymphoma, Non-Hodgkin, Quality of Life. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Krebshilfe, Universitätsklinikum Essen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

When different therapies provide similar cure rates, health-related quality of life (HRQoL) may become crucial for the choice of treatment. In the Positron Emission Tomography-guided Therapy of Aggressive non-Hodgkin Lymphomas (PETAL) trial, we compared six cycles of R-CHOP with or without two extra doses of rituximab in prognostically favorable interim PET (iPET)-negative patients, while eight cycles of R-CHOP were compared with two R-CHOP cycles followed by six cycles of a more intensive protocol in prognostically unfavorable iPET-positive patients. As reported previously, treatment intensification did not improve outcome. HRQoL was assessed using the EORTC QLQ-C30 questionnaire. Pretreatment questionnaires were obtained from 558 out of the 862 participants (64.7%). Pretreatment HRQoL was significantly worse than in the general population. It was associated with age, gender, B symptoms, International Prognostic Index (IPI) and total metabolic tumor volume (TMTV). Physical and cognitive functioning predicted survival independent of IPI or TMTV. During treatment, some domains remained stable (e.g., cognitive functioning, nausea/vomiting), while others improved (e.g., emotional functioning, pain) or deteriorated (e.g., physical functioning, role functioning, fatigue). At the end of treatment, HRQoL was better in patients with controlled disease than in patients with progressive disease and better for iPET-negative patients than for iPET-positive patients. During follow-up, all HRQoL domains returned to levels similar to those reported for the general population. Differences between randomized treatment arms were not observed. The longitudinal data need to be interpreted with caution, because decreasing participation resulted in a selection of patients with increasingly good outcomes. ClinicalTrials.gov no. NCT00554164 (registered 11/5/2007).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsLymphoma, Non-HodgkinQuality of LifeAdultAgedFemaleHumansMaleMiddle AgedAntibodies, Monoclonal, Murine-DerivedCyclophosphamideDoxorubicinPositron-Emission TomographyPrednisoneRituximabSurveys and QuestionnairesVincristine

Stichwörter der Autor:innen

Aggressive non-Hodgkin lymphomaChemotherapyDiffuse large B-cell lymphomaPositron emission tomographyQuality of life

Substanzen

Antibodies, Monoclonal, Murine-DerivedCyclophosphamideDoxorubicinPrednisoneR-CHOP protocolRituximabVincristine

Autor:innen und Institutionen

  • Klinik für Hämatologie und Stammzelltransplantation, Universitätsklinikum Essen, Essen, Germany. ulrich.duehrsen@uk-essen.de.
  • Onkologische Gemeinschaftspraxis, Dresden, Germany.
  • Hämatologisch-onkologische Gemeinschaftspraxis, Halle, Germany.
  • Klinik für Hämatologie/Onkologie und Nephrologie, Friedrich-Ebert-Krankenhaus, Neumünster, Germany.
  • Klinik für Hämatologie und Onkologie, Klinikum Lüdenscheid, Lüdenscheid, Germany.
  • Onkopraxis Probstheida, Leipzig, Germany.

Förderung

  • Deutsche Krebshilfe
  • Universitätsklinikum Essen

Zitieren

APA

Dührsen, U., Prange-Krex, G., Moeller, R., Held, H., Heil, G., Schwarzer, A., Mahlmann, S., Dienst, A., Sandmann, M., Maschmeyer, G., Schütte, J., Hahn, D., Heike, M., Nonnemacher, M., Hanoun, C., Hüttmann, A., & PETAL trial investigators (2025). Health-related quality of life in patients with aggressive non-Hodgkin lymphoma: results from the PETAL trial. Annals of Hematology. https://doi.org/10.1007/s00277-025-06402-1

Vancouver

Dührsen U, Prange-Krex G, Moeller R, Held H, Heil G, Schwarzer A, et al. Health-related quality of life in patients with aggressive non-Hodgkin lymphoma: results from the PETAL trial. Annals of Hematology. 2025. doi:10.1007/s00277-025-06402-1

BibTeX
@article{Dhrsen2025,
  author = {Dührsen, Ulrich and Prange-Krex, Gabriele and Moeller, Regina and Held, Harald and Heil, Gerhard and Schwarzer, Andreas and Mahlmann, Stefan and Dienst, Ariane and Sandmann, Matthias and Maschmeyer, Georg and Schütte, Jochen and Hahn, Dennis and Heike, Michael and Nonnemacher, Michael and Hanoun, Christine and Hüttmann, Andreas and PETAL trial investigators, PETAL trial investigators},
  title = {Health-related quality of life in patients with aggressive non-Hodgkin lymphoma: results from the PETAL trial},
  journal = {Annals of Hematology},
  year = {2025},
  doi = {10.1007/s00277-025-06402-1}
}
Kostenlos starten →